QC
SMMT icon

Quent Capital’s Summit Therapeutics SMMT Stock Holding History

Quent Capital’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26K Buy
155
+50
+48% +$887 ﹤0.01% 1458
2026
Q1 		$1.99K Buy
+105
New +$1.7K ﹤0.01% 1392
2025
Q4 		– Sell
-51
Closed -$1.05K – 1611
2025
Q3 		$1.05K Buy
+51
New +$1.24K ﹤0.01% 1320

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Quent Capital's SMMT Position: Q2 2026 in Review

Quent Capital increased its Summit Therapeutics (SMMT) stake by 48% in Q2 2026, buying an estimated $887 and bringing the position to 155 shares worth $2.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1458.

Quent Capital first reported a position in SMMT in Q3 2025 and has held it in 3 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Quent Capital held 155 shares of Summit Therapeutics worth $2.26K as of Q2 2026.
  • Quent Capital bought 50 Summit Therapeutics shares in Q2 2026, an estimated $887.
  • Summit Therapeutics made up ﹤0.01% of Quent Capital's portfolio in Q2 2026, its #1458 holding.
  • Quent Capital first reported a position in Summit Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.